Chemoprevention strategies for pancreatic cancer

被引：101

作者：

Stan, Silvia D. ^{[1
]}

Singh, Shivendra V. ^{[2
]}

Brand, Randall E. ^{[1
]}

机构：

[1] Univ Pittsburgh, Sch Med, Div Gastroenterol Hepatol & Nutr, Dept Med,Hillman Canc Ctr 2 31, Pittsburgh, PA 15213 USA

[2] Univ Pittsburgh, Sch Med, Dept Pharmacol & Chem Biol, Hillman Canc Ctr 2 31, Pittsburgh, PA 15213 USA

来源：

NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY | 2010年 / 7卷 / 06期

关键词：

FACTOR-KAPPA-B; CELL-CYCLE ARREST; GREEN TEA CONSUMPTION; I CLINICAL-TRIAL; VITAMIN-D; BENZYL ISOTHIOCYANATE; PERILLYL ALCOHOL; GROWTH-FACTOR; CYCLOOXYGENASE-2; EXPRESSION; EPIGALLOCATECHIN GALLATE;

D O I：

10.1038/nrgastro.2010.61

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

Pancreatic cancer has a poor prognosis and is often diagnosed at an advanced stage, which makes it difficult to treat. The low survival rate of patients with pancreatic cancer points towards an increased need for novel therapeutic and chemopreventive strategies and also early detection of this disease. Increased consumption of fruits and vegetables has been associated with a reduced risk of pancreatic cancer. Synthetic and natural, diet-derived bioactive compounds have been evaluated as pancreatic cancer chemopreventive agents and have demonstrated various degrees of efficacy in cellular and in vivo animal models. Some chemopreventive agents (for example, curcumin or resveratrol) have also been reported to sensitize pancreatic cancer cells to standard chemotherapeutic drugs (for example, gemcitabine or erlotinib), which suggests that chemopreventive agents could potentially be used as potentiators of standard chemotherapy. Few clinical trials of pancreatic cancer chemopreventive agents have been completed and some are in early phases. Further development of pancreatic cancer chemopreventive agents may prove to be tremendously valuable for individuals at high risk of developing pancreatic cancer and patients who present with premalignant lesions. This Review discusses the current state of the pancreatic cancer chemoprevention field and highlights the challenges ahead.

引用

页码：347 / 356

页数：10

共 121 条

[41] Peptide YY augments gross inhibition by vitamin E succinate of human pancreatic cancer cell growth [J].

Heisler, T ;

Towfigh, S ;

Simon, N ;

Liu, C ;

McFadden, DW .

JOURNAL OF SURGICAL RESEARCH, 2000, 88 (01) :23-25

[42] Genetics and biology of pancreatic ductal adenocarcinoma [J].

Hezel, Aram F. ;

Kimmelman, Alec C. ;

Stanger, Ben Z. ;

Bardeesy, Nabeel ;

DePinho, Ronald A. .

GENES & DEVELOPMENT, 2006, 20 (10) :1218-1249

[43]

HRUBAN RH, 1993, AM J PATHOL, V143, P545

[44]

Jemal A, 2009, CA-CANCER J CLIN, V59, P225, DOI [10.3322/caac.20006, 10.3322/caac.21387]

[45]

Ji BT, 1997, INT J CANCER, V70, P255, DOI 10.1002/(SICI)1097-0215(19970127)70:3<255::AID-IJC1>3.0.CO

[46]

2-W

[47] Sulforaphane targets pancreatic tumour-initiating cells by NF-κB-induced antiapoptotic signalling [J].

Kallifatidis, G. ;

Rausch, V. ;

Baumann, B. ;

Apel, A. ;

Beckermann, B. M. ;

Groth, A. ;

Mattern, J. ;

Li, Z. ;

Kolb, A. ;

Moldenhauer, G. ;

Altevogt, P. ;

Wirth, T. ;

Werner, J. ;

Schemmer, P. ;

Buechler, M. W. ;

Salnikov, A. V. ;

Herr, I. .

GUT, 2009, 58 (07) :949-963

[48] Vitamin D analogues up-regulate p21 and p27 during growth inhibition of pancreatic cancer cell lines [J].

Kawa, S ;

Nikaido, T ;

Aoki, Y ;

Zhai, Y ;

Kumagai, T ;

Furihata, K ;

Fujii, S ;

Kiyosawa, K .

BRITISH JOURNAL OF CANCER, 1997, 76 (07) :884-889

[49]

Kelloff G J, 1994, J Cell Biochem Suppl, V20, P282

[50]

Kelloff GJ, 1997, CANCER EPIDEM BIOMAR, V6, P267

← 1 2 3 4 5 6 7 8 9 10 →